Poxvirus single-chain fusion immunogen, immunogenic composition containing poxvirus single-chain fusion immunogen and application of poxvirus single-chain fusion immunogen
By designing a single-chain fusion immunogen vaccine containing A35, M1, B6 and A29 antigen epitope, the safety hazards and high production costs of existing monkeypox virus vaccines have been solved, and efficient immune protection effects are achieved, suitable for a large range of Vaccination and vaccination for people with low immunity.
Patent Information
- Application Number
- CN202310621407.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-29
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2043-05-29
AI Technical Summary
The existing monkeypox virus vaccines have problems of safety hazards, uncertainty and high production costs, especially in people with low immunity, and the protection effect of monkeypox virus has not yet been clarified.
Develop a vaccine containing a single-strand fusion immunogen that uses a single-strand fusion immunogen designed by connecting four antigen epitopes (A35, M1, B6 and A29) to combine specific amino acid sequences and tag sequences, using expression The system was cloned and expressed and purified to form an efficient immunogen composition.
The vaccine can efficiently stimulate the specific immune response against monkeypox virus, provide more efficient immune protection, reduce safety risks and production costs, and is suitable for large-scale vaccination, especially in people with low immunity.
Smart Images

Figure SMS_3 
Figure SMS_4 
Figure SMS_5
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a poxvirus single-chain fusion immunogen, an immunogenic composition containing the same, and applications thereof. Background Art
[0002] Monkeypox is a viral zoonosis caused by infection with the Monkeypox virus, with clinical manifestations of fever, rash, and swollen lymph nodes. Since smallpox was eradicated in 1980 and smallpox vaccination was subsequently stopped, monkeypox has become the most important orthopoxvirus in the field of public health, so the development of a vaccine is urgent.
[0003] The poxvirus genome consists of a large linear double-stranded DNA, which is nearly 200kb in length, like the cowpox virus, and can encode up to 200 viral proteins. The morphology of the monkeypox virus is consistent with other orthopoxviruses, with a rounded brick or oval shape, a size of 200nm×250nm, and a 30nm outer membrane surrounding a homogeneous core. Monkeypox virus, smallpox virus, vaccinia virus and cowpox virus are the four viruses in orthopoxvirus that are pathogenic to humans. They all contain soluble antigens, nucleoprotein antigens and hemagglutinins, with basically the same antigenic properties and cross-immunity between them. There are two branches of monkeypox virus in West Africa and the Congo Basin, which have clear epidemiological and clinical prognosis differences. The mortality rate of monkeypox patients in the West African branch is about 3.6%, while the mortality rate of monkeypox patients in the Congo Basin branch can reach 10.6%. The monkeypox epidemic since May 2022 has been sequenced and analyzed, and the virus belongs to the West African branch.
[0004] Poxviruses can produce two forms of infectious virions, termed intracellular mature virions (IMVs) and extracellular enveloped virions (EEVs), both of which contain a core and are surrounded by one (IMV) or two (EEV) lipid membranes. There are more than 20 viral proteins distributed on the membrane of IMVs, most of which are involved in viral attachment and entry. However, EEVs possess a second outer membrane (envelope) that contains at least six unique envelope proteins. IMVs are the major progeny virions released by cell lysis, are structurally stable, and are responsible for mediating host-to-host transmission, whereas EEVs are produced by exocytosis and are thought to be transferred between cells or spread within the host.
[0005] Monkeypox virus (MPXV) belongs to the genus Orthopoxvirus in the Poxviridae family, along with smallpox virus (VARV), vaccinia virus (VACV), and cowpox virus (CPXV). These four viruses are the only ones in the Orthopoxvirus family that can cause human infection. Early vaccines used to eradicate smallpox used live, unattenuated VACV strains produced from calf lymph, such as the Dryvax vaccine; however, these vaccines are no longer produced due to effectiveness and safety issues. Vaccines against smallpox have cross-protective activity against monkeypox. Currently, the FDA has approved two vaccines for pre-exposure vaccination against orthopoxviruses, including monkeypox: JYNNEOS, produced by Ankara-Bavarian Nordic and TM Vaccine (also known as Imvamune or Imvanex) and Sanofi Pasteur Both vaccines are attenuated live vaccines originally used to prevent smallpox; It is a second-generation vaccine that has the ability to replicate in the human body. After vaccination, there is a risk of encephalitis, myocarditis, progressive vaccinia infection, etc. It is not suitable for vaccination of young children, pregnant women and people with low or impaired immune function; JYNNEOS TM As a third-generation vaccine, it cannot replicate in the human body, so its safety is improved compared to the first and second generation vaccines, but its immune effect is also greatly reduced. It is worth noting that the above vaccine products were approved after the eradication of smallpox virus, so they have not been widely vaccinated in the population. Their ability to curb the spread of smallpox virus and monkeypox virus and eradicate the virus remains to be determined.
[0006] In addition to the limited vaccination population and clear vaccination side effects, attenuated live vaccines also have uncertainties and safety risks. First, there is the safety risk caused by the potential mutation of vaccine strains leading to the re-strengthening of virulence; second, poxvirus, as a large nuclear and cytoplasmic DNA virus, has a genome of up to 130-375kbp and encodes up to 200 viral proteins. The antigenic components are extremely complex, and the effective immunogens and mechanisms of action of attenuated live vaccines are unclear, including a variety of viral proteins with immunosuppressive functions, which will have a negative impact on the immunogenicity and protective effects of the vaccine. These safety hazards and uncertainties are particularly evident in people with low immunity, such as the elderly and HIV carriers, and will limit the vaccination of such immune-vulnerable people. At the same time, attenuated live vaccines also face problems such as low production capacity and high cost. Therefore, in view of the severe form of the epidemic and the various drawbacks of existing vaccines, it is urgent to use new technologies to develop a new generation of vaccines with clear immunogen components, clear mechanisms of action, safe, effective and accessible, to help disease prevention and control.
[0007] Therefore, given the severe situation of the epidemic and the various shortcomings of existing vaccines, there is an urgent need to use new technologies to develop a new generation of vaccines with clear immunogenic components, clear mechanisms of action, safety, effectiveness and rapid availability to assist in disease prevention and control.
[0008] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention and should not be regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the invention
[0009] Purpose of the Invention
[0010] In view of the various drawbacks of the existing vaccines, the purpose of the present invention is to provide a single-chain fusion immunogen of monkeypox virus that can efficiently stimulate a specific immune response against monkeypox virus (for example, producing protective antibodies), its related vaccine products, and its preparation method and application; in addition, vaccine products based on the single-chain fusion immunogen also have the advantages of safety, effectiveness, clear immunogen composition and protection mechanism, high production capacity, low cost, etc., thereby meeting the safety and production capacity requirements of large-scale vaccination of emergency vaccine populations.
[0011] Solution
[0012] To achieve the purpose of the present invention, the present invention provides the following technical solutions:
[0013] In a first aspect, the present invention provides a poxvirus single-chain fusion immunogen, the single-chain fusion immunogen comprising an amino acid sequence arranged in the pattern of A35-C1-M1-C2-A35'-C3-A29-C4-B6, wherein:
[0014] A35 represents the monkeypox virus A35 protein or antigenic fragment I thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto,
[0015] A35' represents the monkeypox virus A35 protein or antigenic fragment II thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto,
[0016] M1 represents the monkeypox virus M1 protein or an antigenic fragment thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto,
[0017] B6 represents monkeypox virus B6 protein or an antigenic fragment thereof, or an amino acid sequence that is at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identical thereto and has the same or substantially the same immunogenicity thereto,
[0018] A29 represents the monkeypox virus A29 protein or an antigenic fragment thereof, or an amino acid sequence that is at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identical thereto and has the same or substantially the same immunogenicity thereto,
[0019] C1, C2, C3, and C4 are each independently none or a connecting sequence (GGGGS)n, wherein n is any integer between 1 and 10; and
[0020] in,
[0021] A35 is the same as or different from A35'.
[0022] C1, C2, C3, and C4 are the same or different.
[0023] In some preferred embodiments, the A35 represents the amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 1, and having the same or substantially the same immunogenicity as the amino acid sequence;
[0024] And / or, the A35' represents the amino acid sequence as shown in SEQ ID NO:1, or the amino acid sequence as shown in SEQ ID NO:1 plus the amino acid sequence of a fragment extending 1-30 amino acids therefrom to the N-terminus of the A35 protein, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids from the above amino acid sequence, which has the same or substantially the same immunogenicity as the above amino acid sequence; preferably, the A35' represents the amino acid sequence as shown in SEQ ID NO:2, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids from the amino acid sequence as shown in SEQ ID NO:2, which has the same or substantially the same immunogenicity as the above amino acid sequence;
[0025] And / or, the M1 represents the amino acid sequence as shown in SEQ ID NO: 3, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 3, and having the same or substantially the same immunogenicity as that of the amino acid sequence;
[0026] And / or, B6 represents the amino acid sequence as shown in SEQ ID NO:4, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO:4, and having the same or substantially the same immunogenicity as that of the amino acid sequence;
[0027] And / or, A29 represents the amino acid sequence as shown in SEQ ID NO:5, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO:5, and having the same or substantially the same immunogenicity as that of SEQ ID NO:5.
[0028] Further preferably, the A35 represents the amino acid sequence shown in SEQ ID NO: 1, the A35' represents the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, the M1 represents the amino acid sequence shown in SEQ ID NO: 3, the B6 represents the amino acid sequence shown in SEQ ID NO: 4, and the A29 represents the amino acid sequence shown in SEQ ID NO: 5;
[0029] Preferably, C1, C2, C3, and C4 are all absent;
[0030] Further preferably, the single-chain fusion immunogen comprises the amino acid sequence shown in SEQ ID NO:6.
[0031] Preferably, the N-terminus of the single-chain fusion immunogen further comprises a signal peptide sequence; optionally, the signal peptide sequence is as shown in SEQ ID NO: 9;
[0032] Preferably, the C-terminus of the single-chain fusion immunogen further comprises a tag sequence; optionally, the tag is selected from at least one of a Flag tag, a His tag, a MBP tag, a HA tag, a myc tag, a GST tag, and a SUMO tag, preferably a His tag.
[0033] In the present invention, in order to take into account the immune protection effects against both EEV and IMV virus particles, a single-chain fusion immunogen is designed that simultaneously contains the neutralizing antigens A35 and B6 of EEV and the neutralizing antigens M1 and A29 of IMV. The four neutralizing antigens are encoded by the A35R gene, B6R gene, M1R gene and A29L gene of monkeypox virus, respectively, which are homologous genes to vaccinia virus A33R, B5R, L1R and A27R, respectively.
[0034] In a second aspect, the present invention provides a method for preparing the single-chain fusion immunogen as described in the first aspect, comprising the following steps:
[0035] The Kozak sequence and the coding sequence of the signal peptide are added to the 5' end of the nucleotide sequence encoding the single-chain fusion immunogen as described in the first aspect above, and the coding sequence of the histidine tag and the termination codon are added to the 3' end. Cloning and expression are carried out, and the correct recombinants are screened. They are then transfected into expression system cells for expression, and the cell culture supernatant is collected to isolate the single-chain fusion immunogen.
[0036] In a feasible implementation of the above preparation method, the cells of the expression system are mammalian cells, insect cells, yeast cells or bacterial cells;
[0037] Optionally, the mammalian cell is a HEK293T cell, a 293F series cell or a CHO cell; further optionally, the 293F series cell is a HEK293F cell, a Freestyle293F cell or an Expi293F cell;
[0038] Optionally, the insect cell is a sf9 cell, a Hi5 cell, a sf21 cell or a S2 cell;
[0039] Optionally, the yeast cell is a Pichia pastoris cell or a yeast cell transformed therefrom;
[0040] Optionally, the bacterial cells are Escherichia coli cells.
[0041] In a third aspect, the present invention provides a polynucleotide encoding the single-chain fusion immunogen as described in the first aspect above.
[0042] In a specific embodiment, the polynucleotide is a nucleotide sequence optimized for human codons, which may be DNA or mRNA;
[0043] Preferably, the polynucleotide is a DNA sequence as shown in SEQ ID NO: 7;
[0044] Preferably, the polynucleotide is an mRNA sequence as shown in SEQ ID NO:8.
[0045] In a fourth aspect, the present invention provides a nucleic acid construct comprising the polynucleotide as described in the third aspect above, and optionally, at least one expression control element operably linked to the polynucleotide.
[0046] In a fifth aspect, the present invention provides an expression vector comprising the nucleic acid construct as described in the fourth aspect above.
[0047] In a sixth aspect, the present invention provides a host cell transformed or transfected with the polynucleotide as described in the third aspect, the nucleic acid construct as described in the fourth aspect, or the expression vector as described in the fifth aspect.
[0048] In a seventh aspect, the present invention provides use of the single-chain fusion immunogen described in the first aspect, the polynucleotide described in the third aspect, the nucleic acid construct described in the fourth aspect, the expression vector described in the fifth aspect, or the host cell described in the sixth aspect in the preparation of a drug for preventing and / or treating poxvirus infection;
[0049] Preferably, the poxvirus is selected from the group consisting of: monkeypox virus, smallpox virus, cowpox virus and / or vaccinia virus;
[0050] Optionally, the drug is a vaccine, preferably a recombinant protein vaccine; further preferably, the recombinant protein vaccine uses an adjuvant selected from the following: aluminum adjuvant, MF59 adjuvant and MF59-like adjuvant;
[0051] Optionally, the vaccine is in the form of a nasal spray, oral formulation, suppository or parenteral formulation;
[0052] Preferably, the nasal spray is selected from aerosols, sprays and powder sprays;
[0053] Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film-coated agents and pastes; further preferably, the tablets are sublingual tablets; further preferably, the granules are fine granules; further preferably, the powders are powders; further preferably, the pills are pellets;
[0054] Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid preparation, or an injectable preparation; further preferably, the injectable preparation is a pushable preparation.
[0055] In an eighth aspect, the present invention provides a vaccine or immunogenic composition, comprising the single-chain fusion immunogen as described in the first aspect above, the polynucleotide as described in the third aspect above, the nucleic acid construct as described in the fourth aspect above, the expression vector as described in the fifth aspect above or the host cell as described in the sixth aspect above, and a physiologically acceptable vehicle, adjuvant, excipient, carrier and / or diluent.
[0056] In some preferred embodiments, the vaccine or immunogenic composition is a monkeypox virus recombinant protein vaccine, which comprises the single-chain fusion immunogen and an adjuvant as described in the first aspect above;
[0057] Optionally, the adjuvant is one or more selected from the following adjuvants: aluminum adjuvant, MF59 adjuvant and MF59-like adjuvant.
[0058] In other preferred embodiments, the vaccine or immunogenic composition is a monkeypox virus DNA vaccine comprising:
[0059] (1) a eukaryotic expression vector; and
[0060] (2) a DNA sequence encoding the single-chain fusion immunogen as described in the first aspect constructed and incorporated into the eukaryotic expression vector, preferably a DNA sequence as shown in SEQ ID NO: 7;
[0061] Optionally, the eukaryotic expression vector is selected from pGX0001, pVAX1, pCAGGS and pcDNA series vectors.
[0062] In other preferred embodiments, the vaccine or immunogenic composition is a monkeypox virus mRNA vaccine, and the mRNA vaccine comprises:
[0063] (I) an mRNA sequence encoding the single-chain fusion immunogen as described in the first aspect above, preferably an mRNA sequence as shown in SEQ ID NO: 8; and
[0064] (II) Lipid nanoparticles.
[0065] In other preferred embodiments, the vaccine or immunogenic composition is a monkeypox virus-viral vector vaccine, which comprises:
[0066] (1) viral backbone vectors; and
[0067] (2) a DNA sequence encoding the single-chain fusion immunogen as described in the first aspect constructed into the viral backbone vector, preferably a DNA sequence as shown in SEQ ID NO: 7;
[0068] Optionally, the viral backbone vector is selected from one or more of the following viral vectors: adenovirus vector, poxvirus vector, influenza virus vector, adeno-associated virus vector.
[0069] In a feasible implementation, the vaccine or immunogenic composition is in the form of a nasal spray, an oral preparation, a suppository or a parenteral preparation;
[0070] Preferably, the nasal spray is selected from aerosols, sprays and powder sprays;
[0071] Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film coatings and ointments;
[0072] Further preferably, the tablet is a sublingual tablet;
[0073] Further preferably, the granules are fine granules;
[0074] Further preferably, the powder is a powder;
[0075] Further preferably, the pills are pellets;
[0076] Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid preparation, or an injectable preparation; further preferably, the injectable preparation is a pushable preparation.
[0077] In the ninth aspect, the present invention provides a method for preventing and / or treating poxvirus infection, the method comprising: administering to a subject in need thereof a preventive and / or therapeutically effective amount of the following substances: the single-chain fusion immunogen as described in the first aspect above, the polynucleotide as described in the third aspect above, the nucleic acid construct as described in the fourth aspect above, the expression vector as described in the fifth aspect above, the host cell as described in the sixth aspect above, and / or the vaccine or immunogenic composition as described in the eighth aspect above.
[0078] The "preventively and / or therapeutically effective amount" may vary depending on the subject of administration, the subject organ, symptoms, the method of administration, etc., and can be determined based on the doctor's judgment, taking into account the type of dosage form, the method of administration, the patient's age and weight, the patient's symptoms, etc.
[0079] Beneficial Effects
[0080] The inventors of the present application have designed a single-chain fusion immunogen against poxvirus (especially monkeypox virus), which comprises four antigenic epitopes fused in series in a specific order: (1) monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment), (2) monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), (3) monkeypox virus B6 protein or its antigenic fragment, and (4) monkeypox virus A29 protein or its antigenic fragment; wherein M1 and A29 are neutralizing antigens specific to intracellular mature virus particles (IMV), and A35 and B6 are neutralizing antigens specific to extracellular envelope virus particles (EEV); a vaccine comprising the two can stimulate an immune response against the two infectious virus particles.
[0081] The two A35 proteins or antigenic fragments thereof contained in the single-chain fusion immunogen of the present invention can form a stable intramolecular dimerization form, which is necessary for stimulating a class of neutralizing antibodies against the A35 antigen, and also reverses the problem of lack of immunogenicity when immunizing the A35 protein antigen alone.
[0082] In addition, the fusion immunogen of the present invention can induce the production of balanced and high-level specific antibodies against the above-mentioned four antigenic epitopes; and, compared with immunization with the four antigenic proteins alone, it can stimulate more efficient immune protection, which is manifested in that: at the same immunization dose (for example, 10 μg / dose in the embodiment), due to the difference in molecular weight, the effective molar number of antigenic protein when the antigenic protein is immunized alone is several times that of the fusion immunogen (for example, at an immunization dose of 10 μg / dose, for the M1 antigen protein, it is about 3 times that of the fusion immunogen, for the A35 antigen protein, it is about 2.4 times, for the B6 antigen protein, it is about 2 times, and for the A29 antigen protein, it is about 3.75 times), but the fusion immunogen can still stimulate similar or better specific antibody levels and protective antibody levels as when the antigen protein is immunized alone, thereby achieving unexpectedly more efficient immune protection.
[0083] Compared with the poxvirus vaccines in the prior art, the vaccine products based on the single-chain fusion immunogen of the present invention have the following advantages:
[0084] 1) Subunit vaccines have better safety, thus overcoming the safety issues of existing attenuated live virus vaccines; at the same time, compared with attenuated live virus vaccines, subunit vaccines have the advantages of low production cost, rapid response and production capacity support; experimental verification shows that the poxvirus vaccine of the present invention has good effectiveness;
[0085] 2) The antigen sequence of the monkeypox virus itself is used to have a high specificity for the monkeypox virus; the existing live virus vaccines are basically developed based on vaccinia virus. Although vaccinia virus and monkeypox virus belong to the same Poxviridae family, there are still certain differences in the neutralizing antigen sequences and antigenic epitopes of the two. Therefore, their protective effects against monkeypox virus have yet to be clarified. The poxvirus vaccine of the present invention is developed based on the antigenic epitopes of the monkeypox virus. Therefore, it has a high specificity for the prevention and treatment of monkeypox virus;
[0086] 3) There are many kinds of proteins in monkeypox virus, most of which cannot stimulate effective antiviral immune response, that is, ineffective components. In addition, some viral proteins have immunosuppressive effects. Existing live virus vaccines cannot remove the above-mentioned ineffective and harmful components, so there are risks and uncertainties in vaccination. The poxvirus vaccine of the present invention only retains 4 virus neutralizing antigens. Experimental data show that it can efficiently, stably and evenly stimulate specific antibodies against these 4 antigens, and can show complete protective effects in mouse disease models.
[0087] In addition, compared with mixed immunogens of multiple antigenic proteins, the single-chain fusion immunogen of the present invention also has the following significant advantages:
[0088] 1) When mixed immunogens are used for immunization, due to the differences in expression efficiency of different antigens on the mRNA technology platform, the differences in molecular weight and stability of each antigen on the protein and mRNA technology platform, the different antigens will have different degrees of stimulation of the body's immune response. Therefore, the bioavailability of each antigen will vary greatly, making it impossible to achieve balanced immunity among the antigens. However, the single-chain fusion immune principle of the present invention does not have the above problems.
[0089] 2) The single-chain fusion immunogen of the present invention is more conducive to commercialization. The construction of production cell lines, preclinical evaluation of safety, product quality control, etc. only need to be done for one product, while the mixed immunization principle requires multiple times the workload and cost.
[0090] At the same time, the B6 and A29 antigen fragments contained in the single-chain fusion immunogen of the present invention have been specifically modified. After this modification, the obtained antigen retains its antigenicity and neutralizing epitope while avoiding unstable factors such as oligomerization caused by its own structure or sequence, so that the constructed single-chain fusion immunogen is expressed as a uniform monomer molecule in accordance with expectations, meeting the requirements for protein uniformity in the subsequent subunit vaccine development. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.
[0092] Figure 1 The gel filtration chromatography elution curve and SDS-PAGE identification result of the immunogenic protein AMAb2a expressed in Example 2 of the present invention are shown.
[0093] Figure 2 The gel filtration chromatography elution curves and SDS-PAGE identification results of the single immunogenic proteins A35 (A), B6 (B), A29 (C) and M1 (D) expressed in Example 2 of the present invention are shown.
[0094] Figure 3 The immunogenic protein AMAb2a detected by ELISA method in Example 3 of the present invention respectively shows the binding ability of neutralizing antibodies A27D7 (A), 7D11 (B), Anti-B6 (C) and Anti-A29 (D) against four antigen epitopes (A35, M1, B6, A29); E is the EC of AMAb2a binding to each antibody 50 A list of values.
[0095] Figure 4It is a schematic diagram of the mouse immunization and virus attack strategy used in Example 4 and Example 7 of the present invention.
[0096] Figure 5 The specific binding antibody titers of each immune mouse serum tested in Example 5 of the present invention against each antigen A35 (A), M1 (B), B6 (C) and A29 (D) are shown; wherein the ordinate shows the endpoint antibody titer (Log10) and the abscissa shows each immune group.
[0097] Figure 6 The neutralizing antibody titers of the sera of each immune mouse tested in Example 6 of the present invention against the live VACV virus are shown; wherein the ordinate shows PRNT 50 (log10) values, the horizontal axis shows the immune groups.
[0098] Figure 7 The results show that the immunogens described in Example 7 of the present invention have a high lethal dose (30LD5, 8×10 5 Figure 3 shows the protective effect of BALB / c mice challenged with intranasal drops of VACV-WR virus (PFU) after infection, wherein the horizontal axis shows the number of days after infection, and the vertical axis shows the percentage of weight change (A) and survival rate (B) of mice. The legend of each curve is shown on the right side of Figure B. DETAILED DESCRIPTION
[0099] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0100] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.
[0101] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.
[0102] Example 1: Immunogen design
[0103] In this embodiment, as a representative example of the present invention, two A35 peptide segments, one M1 peptide segment, one B6 peptide segment and one A29 peptide segment are connected in series in the arrangement of A35-M1-A35-B6-A29 from N-terminus to C-terminus, and the single-chain fusion peptide formed can form A35-A35 intramolecular dimerization, hereinafter referred to as AMAb2a, which represents the single-chain fusion immunogen of the present invention.
[0104] The following sequences all use the sequence of the monkeypox virus isolate MPXV_USA_2022_MA001, and the GenBank number of the complete genome of the virus is ON563414.3.
[0105] In the AMAb2a, the two A35 peptide segments use different A35 protein segments, one is the S90-T181 segment of the A35 protein (its amino acid sequence is shown in SEQ ID NO:1), and the other is the S64-T181 segment of the A35 protein (its amino acid sequence is shown in SEQ ID NO:2), the amino acid sequence of the M1 peptide segment is shown in SEQ ID NO:3, the amino acid sequence of the B6 peptide segment is shown in SEQ ID NO:4, and the amino acid sequence of the A29 peptide segment is shown in SEQ ID NO:5; therefore, the amino acid sequence of the AMAb2a is shown in SEQ ID NO:6.
[0106] In the process of constructing the AMAb2a, for the needs of protein expression and purification, the inventors also added a signal peptide sequence (as shown in SEQ ID NO:9) to the N-terminus of the AMAb2a amino acid sequence as shown in SEQ ID NO:6, and added 8 histidine tags to its C-terminus, thereby forming a complete construct as shown in SEQ ID NO:10 below:
[0107] The complete construct of AMAb2a (SEQ ID NO:10)
[0108] Among them, the first underlined part is the signal peptide sequence, the first bold paragraph is the first A35 peptide sequence (S89-T180), the second underlined paragraph is the M1 peptide sequence (A2-G181), the second bold paragraph is the second A35 peptide sequence (S63-T180), the italic is the B6 peptide sequence (T20-A128), the third bold paragraph is the A29 peptide sequence (M1-N43), and the last underlined part is the histidine tag sequence.
[0109] In addition, for comparison, this example also designed expression constructs of single antigen A35, M1, A29 and B6 peptide segments, and their amino acid sequences are as follows:
[0110] Amino acid sequence of A35 peptide construct (SEQ ID NO: 11):
[0111] Among them, the first italic part is the signal peptide sequence, the middle bold part is the A35 peptide sequence, and the last underlined part is the histidine tag sequence for purification.
[0112] Amino acid sequence of the M1 peptide construct (SEQ ID NO: 12):
[0113] Among them, the italic part in front is the tag sequence for purification, and the bold part in the back is the M1 peptide sequence.
[0114] Amino acid sequence of A29 peptide construct (SEQ ID NO: 13):
[0115] Among them, the bold part is the A29 peptide sequence, and the italic part is the tag sequence for purification.
[0116] Amino acid sequence of B6 peptide construct (SEQ ID NO: 14):
[0117] Among them, the italic part in front is the signal peptide sequence, the bold part in the middle is the B6 peptide sequence, and the underlined part at the back is the histidine tag for purification.
[0118] Example 2: Expression and purification of immunogenic protein
[0119] Expression and purification of construct AMAb2a
[0120] The amino acid sequence of the construct AMAb2a designed in Example 1 was optimized for human codons to obtain a nucleotide sequence encoding AMAab2, as shown in SEQ ID NO: 15; a Kozak sequence (GCCACC) was added to the 5' end of the nucleotide sequence and a translation stop codon was added to the 3' end, and then an artificially synthesized DNA fragment was cloned between the EcoRI and XhoI restriction sites of the pCAGGS vector to obtain an expression plasmid for the construct AMAb2a.
[0121] The expression plasmid of AMAb2a was transfected into 293F cells for in vitro recombinant expression. 5-7 days after transfection, the cell supernatant containing the expressed immunogenic protein was collected. Then, the protein was purified. Specifically, the cell supernatant containing the immunogenic protein was purified by nickel ion affinity chromatography (HisTrap TM HP (GE)), and then further purified by gel filtration chromatography column Superdex200 10 / 300GL (GE)). Finally, the protein purity and molecular weight were identified by SDS-PAGE.
[0122] The elution curve of gel filtration chromatography and the SDS-PAGE identification results are as follows Figure 1 As shown, Figure 1 It was shown that after two-step purification, highly pure AMAb2a protein with a molecular weight of ∼75 kDa could be obtained, which was in line with expectations.
[0123] Expression and purification of single immunogens A35, M1, A29 and B6
[0124] The amino acid sequences of the single antigenic peptides A35, M1, A29 and B6 designed in Example 1 were codon optimized for Escherichia coli (M1) and human (A35, B6, A29), respectively, to obtain nucleotide sequences encoding them, as shown in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19, respectively; a translation stop codon was added to the 3' end of these nucleotide sequences, and then these DNA fragments were artificially synthesized and cloned into pCAGGS (A35, B6, A29) or pET-28a expression vectors (M1) to obtain expression plasmids of A35, M1, A29 and B6.
[0125] The expression and purification process of A35, B6, and A29 was consistent with that of AMAb2a. The elution curve of gel filtration chromatography and the SDS-PAGE identification results are shown in Figure 2 As shown in A, 2B, and 2C; Figure 2A, 2B, and 2C show that after two steps of purification, highly pure A35, B6, and A29 proteins can be obtained. The A35 protein was identified by SDS-PAGE, and the molecular weight of the monomer was ~15kDa. The molecular weight corresponding to the elution peak of gel filtration chromatography was ~30kDa, indicating that it was in the form of a dimer. The ability of A35 to form dimers has been confirmed in the structure of its poxvirus homologous protein A33. The B6 protein was purified by Hiload 16 / 60superdex 200PG gel strain, and the elution peak and SDS-PAGE identification results showed that its molecular weight was ~40kDa, and it existed in the form of a monomer in the solution. The A29 protein was purified by Hiload 16 / 60superdex 200PG gel strain, and the SDS-PAGE identification results showed that its molecular weight was ~20kDa, and there were two bands, which may be caused by different glycosylation forms; at the same time, the molecular weight corresponding to its elution peak was greater than 70kDa, which suggested that the A29 protein existed in the form of a uniform multimer in the solution. The ability of A29 to form polymers has been confirmed in the structure of its poxvirus homologous protein A27. The above expression and purification results were in line with expectations.
[0126] The expression and purification process of M1 is as follows: the expression plasmid of M1 is expressed by the E. coli system, and the formed inclusion bodies are renatured in vitro to active protein M1 by arginine dilution renaturation method; then, the renatured M1 protein is purified by gel filtration chromatography column Superdex200 100 / 300GL, and finally, the protein purity and molecular weight are identified by SDS-PAGE. The elution curve of gel filtration chromatography and the identification results of SDS-PAGE are shown in Figure 2 D. Figure 2 D shows that after the above gel filtration chromatography purification, high-purity M1 protein can be obtained; its peak position and SDS-PAGE both show ~25 kDa, which is in line with expectations.
[0127] Example 3: Antigenicity Detection of Immunogens
[0128] In order to detect the exposure and antigenicity of each antigenic epitope of the single-chain fusion immunogen of the present invention, in this example, the immunogen proteins expressed and purified in Example 2 (including the single-chain fusion immunogen protein AMAb2a and the single antigenic proteins A35, M1, A29 and B6) were tested for their binding ability to each epitope neutralizing antibody by ELISA experimental method; wherein, 7D11 and A27D7 antibodies are neutralizing antibodies to vaccinia virus antigens L1 and A33, respectively (see Hua-Poo Su et al., Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein, Virology 368 (2007) 331-341; and Michael H. Matho et al., Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer, PLOS Pathogens|DOI: 10.1371 / journal.ppat.1005148 September, respectively). 1, 2015), data showed that they can cross-recognize the M1 and A35 antigens of monkeypox virus, among which antibody A27D7 can recognize the dimer epitope of A35; antibodies against A29 and B6 antigens were obtained by our laboratory through screening of immunized mice.
[0129] The results are as follows Figure 3 shown.
[0130] Depend on Figure 3 It can be seen that the fusion immunogen AMAb2a showed similar binding ability to the A35 epitope antibody (A27D7), M1 epitope antibody (7D11), B6 epitope antibody (Anti-B6) and A29 epitope antibody (Anti-A29) as the individual A35, M1, B6 and A29 antigen proteins. The EC values of the ELISA binding curves were 50 The values are at similar levels.
[0131] The above data show that the four antigenic epitopes on the single-chain fusion immunogen AMAb2a of the present invention can be well exposed and have high antigenicity.
[0132] Example 4: Mouse immunization experiment
[0133] To verify the immune protection efficacy of the single-chain fusion immunogen of the present invention, the inventors respectively mixed the immunogen proteins obtained in Example 2 with AddaVax TM Adjuvants are mixed and emulsified according to Figure 4The replication-competent vaccinia virus Tiantan strain (VACV-VTT) was used as the attenuated live vaccine control group.
[0134] In the immunization experiment, all mice used were female BALB / c mice, aged 6-8 weeks, with an average weight of 15-20 g. Each experimental group used 8 mice. Figure 5 As shown, mice were immunized on day 0, day 21 and day 42, for a total of 3 times, with each dose of 10 μg per mouse; the vaccination method was intramuscular injection, the injection site was located in the thigh of the mouse, and 50 μL was injected into each leg.
[0135] VACV-VTT was used to immunize mice by scratching the base of the tail. Specifically, the immunization was performed on day 0, with a total immunization dose of 10 7 PFU / piece.
[0136] On the second and third immunizations and two days before the challenge (i.e., days 19, 40, and 61), blood was collected from the eye sockets of all groups of mice. After standing and clotting, the blood was centrifuged at 1500 rpm for 10 minutes to obtain mouse serum, which was immediately packaged and stored in a -80°C refrigerator for subsequent ELISA detection of specific antibody titers and live virus neutralization ability determination.
[0137] Example 5: ELISA test to detect the specific antibody titer induced by the vaccine
[0138] Each immunogenic protein used for mouse immunization (i.e., single antigen proteins A35, M1, A29, B6) was diluted to 2 μg / mL with ELISA coating solution (Solabo, C1050), and 100 μL of the diluted immunogenic protein was added to each well of a 96-well ELISA plate (Corning, 3590), and the plate was allowed to stand overnight at 4°C; the coating solution was discarded, PBS was added to wash away the residual coating solution, and 100 μL of ELISA blocking solution (10% skim milk powder prepared in PBST) was added, and the plate was allowed to stand at room temperature for 1 hour for blocking. During the blocking period, the immune mouse serum obtained in Example 4 was diluted with ELISA blocking solution, and 3 times dilution was performed from 200 times, and 11 dilutions were made for each sample; after the blocking was completed, the blocking solution was removed, and the immune mouse serum diluted 10 times with the blocking solution was added to the ELISA plate, 100 μL for each dilution, incubated at room temperature for 1 hour, and then washed 3 times with PBST; then, HRP-labeled goat anti-mouse secondary antibody (Abcam, ab6789) diluted with blocking solution 1:4000 was added, incubated at room temperature for 1 hour, then washed 5-6 times with PBST, TMB color developing solution was added for color development, and 2M hydrochloric acid was added after the reaction for an appropriate time to terminate the reaction. OD450 readings were detected on an enzyme reader. OD450 values greater than 2.5 times of the negative control were judged to be positive, and the highest dilution multiple of the serum judged to be positive was defined as the serum antibody titer (Endpoint titer). When the reaction value of the lowest dilution factor is still less than 2.5 times that of the negative control, the titer of the sample is defined as half of the lowest dilution factor, that is, Log10=1.
[0139] The results of the specific antibody titer test against each antigen epitope in the serum of mice immunized with each immunogenic protein are as follows: Figure 5 shown by Figure 5 It can be seen that: the single-chain fusion antigen AMAb2a of the present invention can stimulate specific antibodies against four antigenic epitopes in a balanced manner and has good immunogenicity; the stimulation ability of AMAb2a for four epitope-specific antibodies is higher than that of the live virus immunization group; at the same time, AMAb2a greatly reversed the problem of poor immunogenicity when A35 was immunized alone; both single immunization and fusion immunogen immunization were 10ug / dose, but due to the difference in molecular weight, the molar number of effective antigen protein in single immunization was about 3 times (M1), 2.4 times (A35), 3.75 times (A29) or 2 times (B6) that of fusion immunogen immunization, but the fusion immunogen AMAab2 can still stimulate specific antibody levels similar to those of single immunization.
[0140] Example 6: Determination of VACV live virus neutralization ability of immune serum
[0141] Vaccinia virus (VACV) is a model virus of the poxvirus genus. Since the main immunogens of the poxvirus genus have high homology, the vaccinia virus with a low biosafety level and easy operation is usually used for the evaluation of the neutralization ability of other poxvirus vaccines at the cellular level and the evaluation of the protective efficacy in the mouse model. Therefore, in this example, the vaccinia virus mouse-adapted strain Western Reserve (VACV-WR) commonly used internationally was used to determine the neutralization ability of each immunogen protein at the cellular level.
[0142] The immune mouse serum obtained in Example 4 was diluted with a culture medium (DMEM) containing 2% inactivated serum, and 2-fold dilutions were performed from 20 times, and 10 dilutions were made for each sample. The VACV-WR virus was also diluted to 500 PFU / mL with the same diluent. Take 200 μL of the diluted immune mouse serum (the diluent without immune mouse serum was used as a control well) and mix it with 200 μL of the diluted virus solution, and incubate at 37°C for 1 hour. Vero cells were planted in a 12-well plate one day in advance, and the density was about 95% on the second day. The culture medium in the 12-well plate was discarded, and after washing the residual culture medium with PBS, the incubated serum-virus mixture was added to the 12-well plate and infected at 37°C for 2 hours. After infection, the virus-serum mixture was removed, the residual virus was washed with PBS, and the prepared carboxymethyl cellulose-DMEM mixture (2% carboxymethyl cellulose and 2×DMEM were mixed in a 1:1 ratio) was added, and cultured at 37°C for 48-60 hours. After obvious CPE was observed under a microscope, 4% paraformaldehyde fixative was added and fixed at room temperature for 2 hours, followed by crystal violet staining and counting.
[0143] PRNT 50 The calculation method is as follows: the wells containing only the virus are used as the control wells, and the number of plaques counted in all experimental wells is divided by the number of plaques in the control wells, which is the inhibition rate of the serum for the virus in each experimental well. Then, the PRNT is calculated using the log (inhibitor) vs. normalized response--Variable slope formula in the GraphPad software. 50 .
[0144] Results Figure 6 .
[0145] Since the live virus neutralization experiment used the VACV-WR strain, which hardly produces EEV, our neutralization experiments all used IMV virus particles. Since A35 and B6 do not exist on IMV virus particles, we did not test the neutralization ability of A35 and B6 immune group sera.
[0146] like Figure 6As shown, the A29, M1, AMAb2a and live vaccine immunization groups can all produce neutralizing antibodies against IMV virus particles, among which the neutralizing antibody stimulation ability of AMAb2a is significantly higher than that of the live vaccine VACV-VTT and A29 immunization groups.
[0147] Example 7: Challenge protection experiment
[0148] like Figure 5 As shown, the mice immunized three times in Example 4 were given a high lethal dose of 8×10 5 PFU / mouse (30LD50) of VACV-WR virus was used to evaluate the protective effect of the vaccine in the animal model. The results of the weight change percentage and survival percentage of mice in each challenge experimental group are shown in Figure 7 .
[0149] Figure 7 The results show that:
[0150] 1) The single antigen A35 immunization group and the single antigen A29 immunization group had no protective effect on mice infected with VACV-WR virus, and all mice died 6 days after the virus challenge. This shows that although the two antigens can stimulate specific antibody levels after three immunizations (among which, the A29 specific antibody level stimulated by the single antigen A29 is higher than that of the AMAb2a group), they still cannot provide comprehensive protection against the lethal infection of VACV-WR.
[0151] 2) In the single antigen M1 immunization group, the survival rate of mice was 87.5% (7 / 8), but the mice experienced significant weight changes; these results indicate that although M1 immunization alone can stimulate high levels of specific antibodies and has an advantage in cellular neutralization ability among all immunization groups, it still cannot provide comprehensive protection against lethal infection of VACV-WR;
[0152] 3) In the single antigen B6 immunization group and the attenuated live vaccine immunization group, although the mouse survival rate was 100%, the mice experienced significant weight changes on days 3-6 (VACV-VTT group) or days 3-8 (B6 immunization group) after challenge;
[0153] 4) Compared with the above-mentioned immunization group, the single-chain fusion immunogen AMAb2a of the present application had a 100% protective effect on VACV-WR-infected mice, and the mice did not show obvious weight changes.
[0154] The above results show that the single-chain fusion immunogen AMAb2a of the present invention exhibits an excellent protective effect in a mouse model, and thus has excellent application prospects in the preparation of poxvirus vaccines to prevent poxvirus infections including monkeypox virus.
[0155] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the present invention.
[0156] Sequences involved in this application:
[0157] SEQ ID NO: 1 (amino acid sequence of the first A35 peptide segment in AMAb2a)
[0158] STTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCT
[0159] SEQ ID NO:2 (amino acid sequence of the second A35 peptide segment in AMAb2a)
[0160] SANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCT
[0161] SEQ ID NO:3 (amino acid sequence of the M1 peptide in AMAb2a)
[0162] AAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSKGNCAIKALMQLTTKATTQIAPRQVAG
[0163] SEQ ID NO:4 (amino acid sequence of peptide B6 in AMAb2a)
[0164] TCTVPTMNNAKLTSTETSFNDKQKVTFTCDSGYHSLDPNAVCETDKWKYENPCKKMCTVSDYVSELYDKPLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNA
[0165] SEQ ID NO:5 (amino acid sequence of peptide A29 in AMAb2a)
[0166] MDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDN
[0167] SEQ ID NO:6 (amino acid sequence of AMAb2a)
[0168] STTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTTCTVPTMNNAKLTSTETSFNDKQKVTFTCDSGYHSLDPNAVCETDKWKYENPCKKMCTVSDYVSELYDKPLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDN
[0169] SEQ ID NO:7 (DNA sequence encoding AMAb2a as shown in SEQ ID NO:6)
[0170]
[0171] SEQ ID NO:8 (mRNA sequence encoding AMAab2 as shown in SEQ ID NO:6)
[0172]
[0173] SEQ ID NO:9 (amino acid sequence of signal peptide)
[0174] METDTLLLWVLLLWVPGSTG
[0175] SEQ ID NO: 10 (amino acid sequence of the complete construct of AMAb2a in Example 1)
[0176] METDTLLLWVLLLWVPGSTGSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGSANKAAITDSAVAVAAASSTHRKVVSSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTTCTVPTMNNAKLTSTETSFNDKQKVTFTCDSGYHSLDPNAVCETDKWKYENPCKKMCTVSDYVSELYDKPLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAMDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNHHHHHHHH
[0177] SEQ ID NO: 11 (amino acid sequence of the single antigen A35 peptide segment in Example 1)
[0178] METDTLLLWVLLLWVPGSTGSTTQYDHKESCNGLYYQGSCYILHSDYKSFEDAKANCAAESSTLPNKSDVLTTWLIDYVEDTWGSDGNPITKTTSDYQDSDVSQEVRKYFCTHHHHHH
[0179] SEQ ID NO: 12 (amino acid sequence of the single antigen M1 peptide segment in Example 1)
[0180] MGSSHHHHHHSSGLVPRGSHMGAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNITVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAG
[0181] SEQ ID NO: 13 (amino acid sequence of the single antigen A29 peptide in Example 1)
[0182] MDGTLFPGDDDLAIPATEFFSTKAAKNPETKREAIVKAYGDDNEETLKQRLTNLEKKITNITTKFEQIEKSSKRNDEVLFRLENHAETLRAAMISLAKKIDVQTGRHPYELVPRGSGWSHPQFEKGGGSGGGSGGSAWSHPQFEK
[0183] SEQ ID NO: 14 (amino acid sequence of the single antigen B6 peptide segment in Example 1)
[0184] MGAGATGRAMDGPRLLLLLLLGVSLGGAASTCTVPTMNNAKLTSTETSFNDKQKVTFTCDSGYHSLDPNAVCETDKWKYENPCKKMCTVSDYVSELYDKPLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAECQPLQLEHGSCQPVKEKYSFGEYMTINCDVGYEVIGVSYISCTANSWNVIPSCQQKCDIPSLSNGLISGSTFSIGGVIHLSCKSGFTLTGSPSSTCIDGKWNPILPTCVRSNEEFDPVDDGPDDETDLSKLSKDVVQYEQEIESLEATYHHHHHHHH
[0185] SEQ ID NO: 15 (nucleotide sequence encoding the complete construct of AMAb2a)
[0186]
[0187] SEQ ID NO: 16 (nucleotide sequence encoding a single antigen A35 peptide segment (i.e., SEQ ID NO: 11))
[0188] ATGGAAACAGACACCCTGCTGCTGTGGGTCCTGCTGCTCTGGGTGCCTGGCAGCACCGGCAGCACCACCCAGTACGACCACAAAGAGAGCTGCAACGGCCTGTACTACCAAGGCTCTTGTTACATCCTGCACAGCGACTATAAGAGCTTCGAGGATGCTAAGGCCAATTGCGCCGCCGAGAGCAGCACACTGCCTAACAAGTCCGACGTGCTGACCACCTGGCTGATCGACTACGTGGAAGATACATGGGGAAGCGACGGCAACCCCATCACAAAAACCACAAGCGATTATCAGGACAGCGACGTGTCTCAGGAGGTTAGAAAGTACTTTTGCACCCACCACCACCACCACCAT
[0189] SEQ ID NO: 17 (nucleotide sequence encoding a single antigen M1 peptide segment (i.e., SEQ ID NO: 12))
[0190] atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatgggagcagctgcgtcaatacaaacaactgtaaacaccctgagcgaacgtattagctccaaacttgagcaagaggcaaacgcgagcgcgcaaacgaaatgcgatattgagatcggcaacttctatatccgccaaaatcacggttgtaatattaccgtcaagaacatgtgcagcgcggacgcggacgcgcagctggacgccgttttgtctgcagcgaccgaaacctattccggtctgaccccggagcagaaagcgtacgttccggctatgttcaccgcagcactcaatatccaaaccagcgtcaataccgttgttcgtgattttgaaaattacgtgaagcagacgtgcaactcctcggcggtggtggataacaaactgaagatccaaaacgtgattatcgacgaatgttacggcgctccgggttctccgaccaacttggagtttatcaacactggcagcagcaaaggcaactgcgctattaaggcgctgatgcagctgactacaaaggcgaccacgcagatcgccccacgtcaggtggccggt
[0191] SEQ ID NO: 18 (nucleotide sequence encoding a single antigen A29 peptide segment (i.e., SEQ ID NO: 13))
[0192] atggatggtaccctgttccccggcgatgacgacttggccatccccgcgaccgagtttttctccactaaggcggcgaagaacccggagacaaagcgggaggccatcgtcaaggcgtacggggacgacaatgaggagacgctgaagcagcgtctcacgaacttggagaagaaaattacaaacattacgaccaagttcgagcagattgagaagAgcAgcaagagaaacgatgaagtcctcttccggctggagaatcacgcagagacactaagggctgcgatgatttctctagccaagaagatagacgtccagacggggcgccatccatacgagctggtgcctagaggctctggctggtcccacccccagttcgaaaagggcggcggcagcggcggaggaagcggcggcagcgcctggagccaccctcagttcgagaag
[0193] SEQ ID NO: 19 (nucleotide sequence encoding a single antigen B6 peptide segment (i.e., SEQ ID NO: 14))
[0194] ATGGGGGCAGGTGCCACCGGCCGCGCCATGGACGGGCCGCGCCTGCTGCTGTTGCTGCTTCTGGGGGTGTCCCTTGGAGGTGCCGCTAGCACCTGCACCGTGCCCACCATGAACAACGCCAAGCTGACCAGCACCGAGACAAGCTTCAACGACAAGCAGAAGGTGACCTTCACCTGCGACAGCGGCTACCACAGCCTGGACCCCAACGCCGTGTGCGAGACAGACAAGTGGAAGTACGAGAACCCCTGCAAGAAGATGTGCACCGTGAGCGACTACGTGAGCGAGCTGTACGACAAGCCCCTGTACGAGGTGAACAGCACCATGACCCTGAGCTGCAACGGCGAGACAAAGTACTTCCGGTGCGAGGAGAAGAACGGCAACACCAGCTGGAACGACACCGTGACCTGCCCCAACGCCGAGTGCCAGCCCCTGCAGCTGGAGCACGGCAGCTGCCAGCCCGTGAAGGAGAAGTACAGCTTCGGCGAGTACATGACCATCAACTGCGACGTGGGCTACGAGGTGATCGGCGTGAGCTACATCAGCTGCACCGCCAACAGCTGGAACGTGATCCCCAGCTGCCAGCAGAAGTGCGACATCCCCAGCCTGAGCAACGGCCTGATCAGCGGCAGCACCTTCAGCATCGGCGGCGTGATCCACCTGAGCTGCAAGAGCGGCTTCACCCTGACCGGCAGCCCCAGCAGCACCTGCATCGACGGCAAGTGGAACCCCATCCTGCCCACCTGCGTGCGGAGCAACGAGGAGTTCGACCCCGTGGACGACGGCCCCGACGACGAGACAGACCTGAGCAAGCTGAGCAAGGACGTGGTGCAGTACGAGCAGGAGATCGAGAGCCTGGAGGCCACCTACCACcatCACCACCACCATCATCAC
Claims
1. A poxvirus single-chain fusion immunogen, characterized in that: The single-chain fusion immunogen comprises an amino acid sequence arranged in the pattern of A35-C1-M1-C2-A35'-C3-B6-C4-A29, wherein: A35 represents the monkeypox virus A35 protein or antigenic fragment I thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto, A35' represents the monkeypox virus A35 protein or antigenic fragment II thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto, M1 represents the monkeypox virus M1 protein or an antigenic fragment thereof, or an amino acid sequence having at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identity thereto and having the same or substantially the same immunogenicity thereto, B6 represents monkeypox virus B6 protein or an antigenic fragment thereof, or an amino acid sequence that is at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identical thereto and has the same or substantially the same immunogenicity thereto, A29 represents the monkeypox virus A29 protein or an antigenic fragment thereof, or an amino acid sequence that is at least 90%, 92%, 95%, 96%, 97%, 98% or 99% identical thereto and has the same or substantially the same immunogenicity thereto, C1, C2, C3, and C4 are each independently none or a connecting sequence (GGGGS)n, wherein n is any integer between 1 and 10; and in, A35 is the same as or different from A35'. C1, C2, C3, and C4 are the same or different.
2. The poxvirus single-chain fusion immunogen according to claim 1, characterized in that A35 represents the amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 1, and having the same or substantially the same immunogenicity as that of the amino acid sequence; And / or, the A35' represents the amino acid sequence as shown in SEQ ID NO:1, or the amino acid sequence as shown in SEQ ID NO:1 plus the amino acid sequence of a fragment extending 1-30 amino acids therefrom to the N-terminus of the A35 protein, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids from the above amino acid sequence, which has the same or substantially the same immunogenicity as the above amino acid sequence; preferably, the A35' represents the amino acid sequence as shown in SEQ ID NO:2, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids from the amino acid sequence as shown in SEQ ID NO:2, which has the same or substantially the same immunogenicity as the above amino acid sequence; And / or, the M1 represents the amino acid sequence as shown in SEQ ID NO: 3, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 3, and having the same or substantially the same immunogenicity as that of the amino acid sequence; And / or, B6 represents the amino acid sequence as shown in SEQ ID NO:4, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO:4, and having the same or substantially the same immunogenicity as that of the amino acid sequence; And / or, A29 represents the amino acid sequence as shown in SEQ ID NO:5, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO:5, and having the same or substantially the same immunogenicity as that of SEQ ID NO:
5.
3. The poxvirus single-chain fusion immunogen according to claim 2, characterized in that: A35 represents the amino acid sequence shown in SEQ ID NO: 1, A35' represents the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, M1 represents the amino acid sequence shown in SEQ ID NO: 3, B6 represents the amino acid sequence shown in SEQ ID NO: 4, and A29 represents the amino acid sequence shown in SEQ ID NO: 5; Preferably, C1, C2, C3, and C4 are all absent; Further preferably, the single-chain fusion immunogen comprises the amino acid sequence shown in SEQ ID NO:
6.
4. The poxvirus single-chain fusion immunogen according to any one of claims 1 to 3, characterized in that: The N-terminus of the single-chain fusion immunogen further comprises a signal peptide sequence; optionally, the signal peptide sequence is as shown in SEQ ID NO: 9; And / or, the C-terminus of the single-chain fusion immunogen further comprises a tag sequence; optionally, the tag is selected from at least one of a Flag tag, a His tag, a MBP tag, a HA tag, a myc tag, a GST tag, and a SUMO tag, preferably a His tag.
5. A method for preparing the single-chain fusion immunogen according to any one of claims 1 to 3, comprising the following steps: A Kozak sequence and a signal peptide coding sequence are added to the 5' end of the nucleotide sequence encoding the single-chain fusion immunogen according to any one of claims 1 to 3, and a histidine tag coding sequence and a stop codon are added to the 3' end, and cloned and expressed, and the correct recombinant is screened, and then transfected into expression system cells for expression, and the cell culture supernatant is collected to isolate and obtain the single-chain fusion immunogen.
6. The preparation method according to claim 5, characterized in that: The expression system cells are mammalian cells, insect cells, yeast cells or bacterial cells; Optionally, the mammalian cell is a HEK293T cell, a 293F series cell or a CHO cell; further optionally, the 293F series cell is a HEK293F cell, a Freestyle293F cell or an Expi293F cell; Optionally, the insect cell is a sf9 cell, a Hi5 cell, a sf21 cell or a S2 cell; Optionally, the yeast cell is a Pichia pastoris cell or a yeast cell transformed therefrom; Optionally, the bacterial cells are Escherichia coli cells.
7. A polynucleotide encoding the single-chain fusion immunogen according to any one of claims 1 to 4.
8. The polynucleotide according to claim 7, characterized in that: The polynucleotide is DNA or mRNA; Preferably, the polynucleotide comprises the DNA sequence shown in SEQ ID NO:7; Preferably, the polynucleotide comprises the mRNA sequence shown in SEQ ID NO:
8.
9. A nucleic acid construct comprising the polynucleotide according to claim 7 or 8, and optionally, at least one expression control element operably linked to the polynucleotide. 10 . An expression vector comprising the nucleic acid construct according to claim 9 .
11. A host cell transformed or transfected with the polynucleotide according to claim 7 or 8, the nucleic acid construct according to claim 9 or the expression vector according to claim 10.
12. Use of the single-chain fusion immunogen according to any one of claims 1 to 4, the polynucleotide according to claim 7 or 8, the nucleic acid construct according to claim 9, the expression vector according to claim 10 or the host cell according to claim 11 in the preparation of a medicament for preventing and / or treating poxvirus infection; Preferably, the poxvirus is selected from the group consisting of: monkeypox virus, smallpox virus, cowpox virus and / or vaccinia virus; Optionally, the drug is a vaccine, preferably a recombinant protein vaccine; further preferably, the recombinant protein vaccine uses an adjuvant selected from the following: aluminum adjuvant, MF59 adjuvant and MF59-like adjuvant; Optionally, the vaccine is in the form of a nasal spray, oral formulation, suppository or parenteral formulation; Preferably, the nasal spray is selected from aerosols, sprays and powder sprays; Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film-coated agents and pastes; further preferably, the tablets are sublingual tablets; further preferably, the granules are fine granules; further preferably, the powders are powders; further preferably, the pills are pellets; Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid preparation, or an injectable preparation; further preferably, the injectable preparation is a pushable preparation.
13. A vaccine or immunogenic composition comprising a single-chain fusion immunogen as described in any one of claims 1 to 4, a polynucleotide as described in claim 7 or 8, a nucleic acid construct as described in claim 9, an expression vector as described in claim 10 or a host cell as described in claim 11, and a physiologically acceptable vehicle, adjuvant, excipient, carrier and / or diluent.
14. The vaccine or immunogenic composition according to claim 13, which is a monkeypox virus recombinant protein vaccine, comprising the single-chain fusion immunogen according to any one of claims 1 to 4 and an adjuvant; Optionally, the adjuvant is one or more selected from the following adjuvants: aluminum adjuvant, MF59 adjuvant and MF59-like adjuvant.
15. The vaccine or immunogenic composition according to claim 13, which is a monkeypox virus DNA vaccine, comprising: (1) Eukaryotic expression vector; and (2) a DNA sequence encoding the single-chain fusion immunogen according to any one of claims 1 to 4 constructed into the eukaryotic expression vector, preferably a DNA sequence as shown in SEQ ID NO: 7; Optionally, the eukaryotic expression vector is selected from pGX0001, pVAX1, pCAGGS and pcDNA series vectors.
16. The vaccine or immunogenic composition according to claim 13, which is a monkeypox virus mRNA vaccine, comprising: (I) an mRNA sequence encoding the single-chain fusion immunogen according to any one of claims 1 to 4, preferably an mRNA sequence as shown in SEQ ID NO: 8; and (II) Lipid nanoparticles.
17. The vaccine or immunogenic composition according to claim 13, which is a monkeypox virus-viral vector vaccine, comprising: (1) Viral backbone vector; and (2) a DNA sequence encoding the single-chain fusion immunogen according to any one of claims 1 to 4 constructed into the viral backbone vector, preferably a DNA sequence as shown in SEQ ID NO: 7; Optionally, the viral backbone vector is selected from one or more of the following viral vectors: adenovirus vector, poxvirus vector, influenza virus vector, adeno-associated virus vector.
18. The vaccine or immunogenic composition according to any one of claims 13 to 17, characterized in that The vaccine or immunogenic composition is in the form of a nasal spray, oral formulation, suppository or parenteral formulation; Preferably, the nasal spray is selected from aerosols, sprays and powder sprays; Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film coatings and ointments; Further preferably, the tablet is a sublingual tablet; Further preferably, the granules are fine granules; Further preferably, the powder is a powder; Further preferably, the pills are pellets; Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid preparation, or an injectable preparation; further preferably, the injectable preparation is a pushable preparation.
Citation Information
Patent Citations
Poxvirus multi-antigen chimeric vaccine and application thereof
CN116082521A
Protein vaccines against poxviruses
US20100196491A1
Cited By
Monkey pox virus multi-antigen monovalent vaccine and application thereof
CN119735707A
Bovine nodular skin disease virus recombinant chimeric antigen, immunogenic composition containing bovine nodular skin disease virus recombinant chimeric antigen and application of bovine nodular skin disease virus recombinant chimeric antigen
CN121159712A
